Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call And Webcast

2025-01-27 04:16:57

(MENAFN- PR Newswire)

BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA ) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at . A replay will be available beginning at 8:30 a.m. ET on February 6, 2025.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA ) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, cliQ1-nical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit .

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
[email protected]

Sherry Dinsmore
[email protected]

SOURCE Azenta

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN27012025003732001241ID1109134966

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.